蒿属花粉过敏性哮喘集群免疫治疗的生物标志物及作用机制研究

过敏性哮喘（AA）病患日益增长，气传花粉尤其蒿属花粉过敏是重要原因之一。37%秋季花粉过敏5年内进展为AA，严重危害人民健康。变应原免疫治疗是唯一能改变这种自然进程的干预方法，兼具防、治双重作用。皮下免疫治疗（SCIT）传统方案疗效可靠、安全性肯定，但在经济支出、起效时间方面存在明显瓶颈问题，且疗效评估须在1年后，周期过长。本项目立足蒿属花粉AA防治研究热点，将转录组学和SCIT新方法相结合，评估集群SCIT用于蒿属花粉AA患者疗效与起效机制，筛选预测集群SCIT疗效的中国人群外周血生物标志物，为集群SCIT应用提供支撑依据，为治疗早期精准甄别蒿属花粉AA患者对集群SCIT反应性提供有益借鉴。本项目SCIT新方法实施将有望使中国数以百万计蒿属花粉AA患者从中受益，减少国家医疗财政支出和人民负担，并在国际上首次展示中国人群蒿属花粉AA接受集群SCIT的机制特征，具有很好的科学前景与临床价值。

The prevalence of allergic asthma is increasing, and airborne pollen allergy, especially Artemisia pollen allergy is one of the major causes. 37% autumn pollinosis patients will develop into allergic asthma within five years, which seriously endangers health of Chinese public. Allergen specific immunotherapy is the only way to change this natural process. It has both therapeutic and preventive effects. Conventional subcutaneous immunotherapy is reliable and safe in clinical application, but it has obvious bottlenecks in terms of economic expenditure and onset time. Its efficacy has to be evaluated one year after the administration. Based on the research hotspot of Artemisia pollen-induced allergic asthma prevention and treatment in China, this project combines transcriptome with new treatment of allergen specific immunotherapy, evaluates the efficacy and mechanism of cluster immunotherapy on allergic asthma induced by Artemisia pollen in Chinese population, and screens biomarkers in peripheral blood to predict the efficacy of cluster immunotherapy, so as to provide basis for the application of cluster immunotherapy in China. This study will provide useful reference for early and accurate evaluating the response to cluster immunotherapy among Chinese Artemisia pollen-induced allergic asthma patients. The implementation of the new immunotherapy treatment will benefit millions of Chinese Artemisia pollen-induced allergic asthma patients, and reduce the national medical expenditure and burden. It is the first research on the transcriptomic mechanism of cluster immunotherapy in Chinese Artemisia pollen-induced allergic asthma population in the world, which will generate great scientific prospects and clinical value.